We are live on ! Find out more
SI

Sofinnova Investments Portfolio holdings

AUM $2.63B
1-Year Est. Return 117.41%
This Fund
S&P 500
This Quarter Est. Return
+3.52%
1 Year Est. Return
+117.41%
3 Year Est. Return
+428.82%
5 Year Est. Return
+748.21%
10 Year Est. Return
–
AUM
$1.69B
AUM Growth
-$46.5M
Cap. Flow
-$20.4M
Cap. Flow %
-1.21%
Top 10 Hldgs %
61.89%
Holding
89
New
22
Increased
14
Reduced
20
Closed
19

Top Buys

Rank Stock Value
1
ABBV icon
AbbVie
ABBV
+$31.1M
2
BPMC
Blueprint Medicines
BPMC
+$16.9M
3
HZNP
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
+$16.3M
4
ZTS icon
Zoetis
ZTS
+$15.3M
5
ZYME icon
Zymeworks
ZYME
+$13.7M

Top Sells

Rank Stock Value
1
XLRN
Acceleron Pharma
XLRN
+$25.4M
2
BIIB icon
Biogen
BIIB
+$25.4M
3
NBIX icon
Neurocrine Biosciences
NBIX
+$19.8M
4
PODD icon
Insulet
PODD
+$19.2M
5
VRTX icon
Vertex Pharmaceuticals
VRTX
+$17.8M

Sector Composition

Rank Sector Weight
1 Healthcare 91.37%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
FATE icon
76
Fate Therapeutics
FATE
$283M
– –
-46,386
Closed -$4.03M
KYNB
77
PUT
Kyntra Bio
KYNB
$28.5M
– –
-8,000
Closed -$5.33M
MGNX icon
78
MacroGenics
MGNX
$254M
– –
-234,504
Closed -$6.3M
MIRM icon
79
Mirum Pharmaceuticals
MIRM
$6.96B
– –
-259,465
Closed -$4.49M
NBIX icon
80
Neurocrine Biosciences
NBIX
$17.7B
– –
-203,200
Closed -$19.8M
OEF icon
81
PUT
iShares S&P 100 ETF
OEF
$19.8B
– –
-325,000
Closed -$53.2M
REPL icon
82
Replimune Group
REPL
$724M
– –
-71,661
Closed -$2.75M
SVRA icon
83
Savara
SVRA
$1.11B
– –
-1,278,424
Closed -$2.17M
VRTX icon
84
Vertex Pharmaceuticals
VRTX
$122B
– –
-88,214
Closed -$17.8M
TCRR
85
DELISTED
TCR2 Therapeutics Inc. Common Stock
TCRR
– –
-296,282
Closed -$4.86M
TCRR
86
PUT
DELISTED
TCR2 Therapeutics Inc. Common Stock
TCRR
– –
-139,700
Closed -$2.29M
OTIC
87
DELISTED
Otonomy, Inc.
OTIC
– –
-1,251,256
Closed -$2.79M
CCXI
88
CALL
DELISTED
ChemoCentryx, Inc.
CCXI
– –
-215,000
Closed -$2.88M
1 2 3
4

Similar funds

WWM
Western Wealth Management Golden, Colorado $2.63B AUM 21.3% 1-Year Est. Return
ACI
Amazon.com Inc Seattle, Washington $2.63B AUM 20.53% 1-Year Est. Return
LOAMS
Lombard Odier Asset Management (Switzerland) Petit-Lancy, Switzerland $2.63B AUM 31.52% 1-Year Est. Return
IA
Integrity Alliance Urbandale, Iowa $2.64B AUM 16.75% 1-Year Est. Return
WCA
Waratah Capital Advisors Toronto, Ontario, Canada $2.63B AUM 76.33% 1-Year Est. Return
ACM
Advance Capital Management Southfield, Michigan $2.64B AUM 13.57% 1-Year Est. Return
NIG
NFJ Investment Group Dallas, Texas $2.64B AUM 23.86% 1-Year Est. Return
WBG
Wharton Business Group Malvern, Pennsylvania $2.65B AUM 20.73% 1-Year Est. Return

Sofinnova Investments's Q3 2021 Portfolio in Review

As of Q3 2021, Sofinnova Investments held 89 positions worth $1.69B, down 2.7% from $1.74B the previous quarter. Its ten largest holdings account for 62% of the portfolio.

Sofinnova Investments's Q3 2021 filing shows 22 new, 14 increased, 20 reduced and 19 closed positions. Its largest new stake was AbbVie: 272,600 shares worth $29.4M. The largest sale was Acceleron Pharma, an estimated $25.4M.

By sector, the portfolio is most concentrated in Healthcare at 91% of assets, down from 94% a quarter earlier.

  • Sofinnova Investments's largest Q3 2021 buy was AbbVie: 272,600 shares worth $29.4M.
  • Sofinnova Investments added most to Heron Therapeutics in Q3 2021, an estimated $10.1M increase.
  • Sofinnova Investments's biggest Q3 2021 reduction was Acceleron Pharma, cutting an estimated $25.4M.
  • Sofinnova Investments fully exited Neurocrine Biosciences in Q3 2021, selling an estimated $19.8M.
  • Sofinnova Investments's ten largest holdings make up 62% of its $1.69B portfolio in Q3 2021.
  • Sofinnova Investments opened 22 new positions and closed 19 in Q3 2021.
  • Sofinnova Investments's portfolio value fell 2.7% quarter-over-quarter to $1.69B.

Based on Sofinnova Investments's 13F filing for Q3 2021, filed 15 Nov 2021.